RxDoctor Payments Data

Sean Collins

Radiation Oncology · Washington, DCNPI 1396764965

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Boston Scientific at 34.6% of the total. Among radiation oncology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$395,087in general payments, 2019–2025

Across 375 payments — averaging $1053.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$137K
  • Sumitomo Pharma America, Inc.$103K
  • Blue Earth Diagnostics$79K
  • Accuray Incorporated$53K
  • Pfizer$11K
  • Myovant Sciences Inc.$5K
  • plus $7K from 10 others
$100,310in research payments, 2019–2025

Across 13 payments — averaging $7716.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Accuray Incorporated$90K
  • Pfizer$10K

What the payments were for

  • Consulting fees$127,53332%
  • Speaking & faculty fees$223,17656%
  • Travel & lodging$31,5578%
  • Food & beverage$12,7303%
  • Entertainment$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$395,087 in reported general payments places this provider in the 95th percentile of 25 radiation oncology providers in District of Columbia.

See all radiation oncology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$342,196
Medicare patients
534
Services billed
3,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl283$5,909
Silodosin20$1,877
Alfuzosin Hcl ErAlfuzosin Hcl21$649
Finasteride13$161
Dexamethasone14$99
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$33

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →